Healthcare providers need to develop a new framework to assess antitrust risks with M&A and other collaborations. We will examine the effects of the proposed merger guidelines, withdrawal of the healthcare policy statements and COPA-sanctioned transactions, as well as identify the overarching principles, recent agency advocacy, and good case law for evaluating provider M&A and collaborations.
Sponsored by the Antitrust Law Section Health Care & Pharmaceuticals Committee.
